# Corporate Partnership Contracts

**Document Version**: 1.0
**Last Updated**: November 9, 2025
**Owner**: Executive Director & Development Director
**Purpose**: Comprehensive framework for establishing, negotiating, and managing corporate partnershipsâ€”including pharmaceutical companies, healthcare corporations, and commercial sponsorsâ€”ensuring mutually beneficial relationships while maintaining Foundation independence, mission integrity, and patient trust.

---

## ðŸ“‹ Table of Contents

1. [Corporate Partnership Philosophy](#corporate-partnership-philosophy)
2. [Types of Corporate Partners](#types-of-corporate-partners)
3. [Partnership Identification & Due Diligence](#partnership-identification--due-diligence)
4. [Pharmaceutical Company Partnerships](#pharmaceutical-company-partnerships)
5. [Healthcare Corporation Partnerships](#healthcare-corporation-partnerships)
6. [Sponsorship Agreements](#sponsorship-agreements)
7. [Brand Guidelines & Co-Branding](#brand-guidelines--co-branding)
8. [Conflicts of Interest Management](#conflicts-of-interest-management)
9. [Foundation Independence Protections](#foundation-independence-protections)
10. [Termination & Exit Clauses](#termination--exit-clauses)
11. [Legal & Tax Considerations](#legal--tax-considerations)
12. [Budget & Resources](#budget--resources)

---

## Corporate Partnership Philosophy

### Why Partner with Corporations?

**Reality**: AATD Foundation needs resources (funding, expertise, patient reach)â€”corporations have resources but want value (brand visibility, patient access, scientific collaboration, CSR/ESG credibility).

**Win-Win**:
- **Foundation Gets**: Funding ($50K-$500K/year), in-kind support (free medications for patient assistance program, lab equipment for research partners), marketing reach (company's social media amplifies Foundation campaigns)
- **Corporation Gets**: Brand association with respected patient organization, insights into patient needs (inform drug development, service design), employee volunteer opportunities, tax deductions, ESG report content

**Core Tension**: Foundation must balance corporate funding (enables mission) with independence (perception = "pharma puppet" destroys patient trust).

---

### Guiding Principles

**1. Mission First, Money Second**
- âœ… Accept corporate partnerships that advance AATD patient outcomes (augmentation therapy manufacturer funds patient educationâ€”good)
- âŒ Decline partnerships that compromise mission (tobacco company wants to sponsorâ€”no, smoking causes COPD, conflicts with lung health mission)

**2. Transparency & Disclosure**
- âœ… Publicly disclose all corporate funders (website lists "Corporate Partners," annual report shows revenue sources)
- âœ… Label sponsored content ("This educational webinar supported by [Company]")
- âŒ Hidden relationships (undisclosed pharma funding = scandal waiting to happen)

**3. Editorial Independence**
- âœ… Foundation retains full control over messaging (company can't approve Foundation's social media posts, policy positions, educational content)
- âŒ "Pay-to-play" (company pays $100K â†’ demands Foundation endorse their drug over competitorsâ€”no)

**4. Patient Trust is Non-Negotiable**
- âœ… If partnership could erode patient trust (perception of bias, conflicts), declineâ€”no amount of money worth destroying reputation
- âœ… Consult patient advisory committee before major corporate partnerships ("Would you trust Foundation if we partnered with X?")

---

## Types of Corporate Partners

### 1. Pharmaceutical Companies

**Profile**: Develop/manufacture AATD-related medications (augmentation therapy, symptomatic treatments, pipeline drugs).

**Partnership Opportunities**:
- **Unrestricted educational grants** ($50K-$250K/yearâ€”fund patient webinars, disease awareness campaigns, support groups, but no drug promotion)
- **Patient assistance programs** (company provides free/discounted medications to uninsured patientsâ€”Foundation refers patients, company fulfills)
- **Research funding** ($100K-$500Kâ€”sponsor investigator-initiated studies, patient registry, real-world evidence research)
- **Conference sponsorship** ($10K-$50Kâ€”support Foundation's annual AATD summit, exhibit booth, speaking slot)

**Typical Partners**: Grifols (augmentation therapy), CSL Behring (augmentation therapy), Takeda (rare disease portfolio), emerging biotech with AATD pipeline drugs

**Conflict Risk**: ðŸ”´ HIGH (perception Foundation favors sponsor's drug over competitors)

---

### 2. Healthcare Corporations

**Profile**: Health systems, diagnostic labs, medical device companies, telehealth platforms.

**Partnership Opportunities**:
- **Genetic testing partnerships** (Foundation promotes AATD genetic testing, lab offers discounted/free testing to Foundation referralsâ€”$50-$100/test vs. $200 retail)
- **Diagnostic device partnerships** (spirometer manufacturer donates devices to Foundation's patient education eventsâ€”patients learn how to measure lung function)
- **Telehealth partnerships** (Foundation negotiates group rates for AATD patientsâ€”$30/visit vs. $75, platform gets patient volume)
- **Health system collaborations** (hospital system with AATD clinic partners with Foundationâ€”co-sponsor patient events, shared social media campaigns)

**Typical Partners**: Quest Diagnostics, LabCorp, pulmonary function test device companies, Teladoc, major health systems (Mayo Clinic, Cleveland Clinic)

**Conflict Risk**: ðŸŸ¡ MODERATE (less controversial than pharma, but must ensure patients not steered to specific provider unfairly)

---

### 3. Commercial Sponsors (Non-Healthcare)

**Profile**: Companies seeking CSR (Corporate Social Responsibility) or cause marketingâ€”not healthcare-related, but want to support rare disease advocacy.

**Partnership Opportunities**:
- **Event sponsorship** ($5K-$50Kâ€”sponsor Foundation's walk/gala, logo on t-shirts, booth at event)
- **Employee engagement** (company's 500 employees volunteer at Foundation events, participate in fundraising campaignsâ€”builds team morale)
- **Matching gifts** (company matches employee donations 1:1 or 2:1â€”doubles impact)
- **Cause marketing** ("$1 from every product sold donated to Mark Egly Foundation"â€”company gets PR, Foundation gets funding + awareness)

**Typical Partners**: Regional businesses (restaurants, retailersâ€”"10% of sales Tuesday benefit Mark Egly Foundation"), corporations with employee giving programs (Google, Microsoft, local banks)

**Conflict Risk**: ðŸŸ¢ LOW (no healthcare conflicts, mostly goodwill + visibility)

---

## Partnership Identification & Due Diligence

### How to Find Corporate Partners

**Inbound** (Companies Approach Foundation):
- **Conference interactions**: Pharma reps at American Thoracic Society conference meet Foundation staff, propose partnership
- **Website inquiries**: "Partner with Us" page generates 5-10 inquiries/year
- **Board connections**: Board member works at pharma company, facilitates introduction

**Outbound** (Foundation Approaches Companies):
- **Strategic targeting**: Foundation identifies companies with AATD products (augmentation therapy manufacturersâ€”3 major players), cold email: "We'd like to discuss partnership opportunities benefiting AATD patients"
- **RFPs**: Foundation issues Request for Proposals ("Seeking pharmaceutical partner for patient education grantâ€”submit proposals by [date]")
- **Broker relationships**: Consultant who specializes in nonprofit-pharma partnerships introduces Foundation to potential funders ($5K-$10K fee if partnership closesâ€”contingency basis)

---

### Due Diligence Checklist

**Before partnering, Foundation investigates**:

**Company Reputation**:
- âœ… **Google search**: Any recent scandals? (FDA warning letters, lawsuits, fraud investigationsâ€”red flags)
- âœ… **Patient community sentiment**: Do AATD patients trust this company? (Facebook group poll: "Would you trust Foundation's partnership with Company X?"â€”if 60%+ say no, reconsider)
- âœ… **Nonprofit partnerships**: Does company have track record partnering with patient organizations? (if yes, contact those orgsâ€”"How was your experience?")

**Financial Stability**:
- âœ… **Public company**: Review 10-K (annual reportâ€”is company profitable, or burning cash and might disappear?)
- âœ… **Private company**: Request financial statements (if asking Foundation to co-develop product, need assurance company won't fold mid-project)

**Values Alignment**:
- âœ… **Mission fit**: Does company's work align with Foundation's mission? (augmentation therapy = yes, tobacco = no)
- âœ… **ESG record**: Does company have environmental/social/governance issues? (pollution, labor violations, discriminatory practicesâ€”conflicts with Foundation values)

**Legal Compliance**:
- âœ… **Debarment check**: Is company barred from federal contracts? (search SAM.govâ€”if debarred, risky partner)
- âœ… **OIG exclusion list**: Is company/executives excluded from Medicare/Medicaid? (healthcare fraudâ€”avoid)

**Decision Matrix**:

| **Company**   | **Reputation** | **Patient Sentiment** | **Financial Stability** | **Mission Fit** | **Risk Level** | **Decision** |
| ------------- | -------------- | --------------------- | ----------------------- | --------------- | -------------- | ------------ |
| Company A     | âœ… Excellent   | âœ… 85% positive       | âœ… Profitable           | âœ… High         | ðŸŸ¢ Low         | **Proceed**  |
| Company B     | âš ï¸ Mixed       | âš ï¸ 60% neutral        | âœ… Stable               | âœ… Moderate     | ðŸŸ¡ Moderate    | **Proceed with caution** |
| Company C     | ðŸš© Scandal (2023) | âŒ 70% negative    | âš ï¸ Unprofitable         | âš ï¸ Weak         | ðŸ”´ High        | **Decline**  |

---

## Pharmaceutical Company Partnerships

### Unrestricted Educational Grants

**What is Unrestricted Grant?**
- Pharma company gives Foundation $100K to fund patient education (webinars, fact sheets, support groups)
- **"Unrestricted" = Foundation controls content** (company can't review/edit materials, can't require drug promotion)
- **Company benefits**: Brand visibility (logo on event materials, "Supported by Company X"), association with patient education (CSR/ESG credits)

---

### Grant Agreement Template

**EDUCATIONAL GRANT AGREEMENT**

**Between**: [Pharmaceutical Company] ("Grantor") and Mark Egly Foundation ("Grantee")

---

**1. GRANT PURPOSE**

Grantor provides unrestricted educational grant to support Grantee's AATD patient education initiatives, including:
- Monthly webinars (AATD disease management, treatment options, self-advocacy)
- Printed educational materials (symptom guides, genetic testing brochures)
- Support group facilitator training
- Annual AATD patient summit

**Total Grant**: $150,000 (one-time or annualâ€”specify)

---

**2. GRANT CONDITIONS**

**Unrestricted**:
- Grant is unrestrictedâ€”Grantee has sole discretion over educational content, speakers, topics
- Grantor may not review or approve materials prior to publication/dissemination
- Grantee will not promote Grantor's products exclusively (may mention as treatment option among othersâ€”balanced, evidence-based)

**Acknowledgment**:
- Grantee will acknowledge Grantor's support: "This program supported by educational grant from [Company]"
- Logo placement: Company logo on event materials, website (sized comparable to other sponsorsâ€”not disproportionately large)

**No Endorsement**:
- Acknowledgment â‰  endorsement (Foundation does not endorse Grantor's products, does not state "preferred" or "recommended")
- If Grantor claims endorsement, Foundation may terminate grant, require corrective statement

---

**3. REPORTING**

**Annual Report** (Within 90 Days of Grant Period End):
- Summary of activities funded (12 webinars, 500 attendees total; 10,000 brochures distributed)
- Patient impact metrics (survey data: 85% reported increased disease knowledge)
- Financial accounting (budget vs. actualâ€”$145K spent of $150K, $5K returned or rolled to next year)

---

**4. TERM & TERMINATION**

**Term**: January 1, 2026 - December 31, 2026 (renewable annually by mutual agreement)

**Termination**:
- **By Grantee**: If Grantor attempts to control content, requires product endorsementâ€”Foundation may terminate with 30 days notice, retain pro-rata funds for work completed
- **By Grantor**: With 90 days notice (e.g., budget cuts)â€”Foundation retains funds for activities already committed

---

**5. INDEPENDENCE**

Grantee retains full editorial and programmatic independence. This grant does not create employment, agency, or partnership relationship.

---

**6. PUBLIC DISCLOSURE**

Both parties will publicly disclose partnership:
- **Foundation**: Lists Grantor on website "Corporate Partners" page, annual report donor list
- **Grantor**: May reference grant in CSR reports, press releases (must share drafts with Foundation for accuracy check)

---

**7. SIGNATURES**

[ED and Company authorized signatory]

---

### Patient Assistance Programs (PAP)

**Model**: Pharma company provides free/discounted AATD medications to uninsured/underinsured patientsâ€”Foundation serves as referral source (identifies eligible patients, helps them apply).

**Foundation's Role**:
- âœ… Patient Navigator screens patients ("Are you insured? Annual income? Drug cost burden?")
- âœ… Foundation refers eligible patients to company's PAP (provides application link, may help complete paperwork)
- âœ… Foundation tracks outcomes (how many patients approved, deniedâ€”if denial rate high, advocate for program improvements)

**Foundation Does NOT**:
- âŒ Receive payment from company for referrals (that's illegal kickback)
- âŒ Exclusively refer to one company's PAP (if multiple AATD drugs available, Foundation provides info on allâ€”patient chooses)

**Contract Key Terms**:
> **Patient Assistance Program Collaboration Agreement**
>
> **Objective**: Improve AATD medication access for uninsured patients.
>
> **Company Responsibilities**:
> - Operate PAP (review applications, approve eligible patients, ship medications directly to patients or pharmacies)
> - Provide Foundation with program brochures, eligibility criteria, application forms
> - Process applications within 10 business days
>
> **Foundation Responsibilities**:
> - Inform patients about PAP (include in patient resource packets, website, navigator calls)
> - Assist patients with application completion (if requested)
> - Collect aggregate data (# referred, # approvedâ€”for program evaluation)
>
> **No Fees**: Foundation does not charge patients or receive compensation from Company for referrals.
>
> **Non-Exclusivity**: Foundation may refer patients to other manufacturers' PAPs (if multiple AATD drugs available, provide all options).

---

### Research Funding

**Model**: Pharma company funds Foundation-managed research (patient registry, real-world evidence study, quality-of-life research).

**Example**: Company grants $300K over 3 years to support AATD Patient Registryâ€”Foundation collects patient data (demographics, genotypes, treatments, outcomes), researchers (academic partners) analyze, publish findings.

**Why Company Funds This**:
- **Real-world evidence**: FDA increasingly wants RWE (how drugs perform outside clinical trials)â€”registry data supplements clinical trial data
- **Post-market surveillance**: Track long-term safety, efficacy (augmentation therapy patients: what % have stable lung function at 5 years?)
- **Competitive intelligence**: Understand patient population (how many use competitor's drug, combination therapies)

**Foundation's Protections**:
- âœ… **Data ownership**: Foundation owns registry data (company gets access to aggregated, de-identified dataâ€”not patient-level identifiable data)
- âœ… **Publication rights**: Foundation + academic researchers publish findings (company cannot block publication of unfavorable resultsâ€”e.g., "Drug X users have same outcomes as Drug Y"â€”company might dislike, but can't censor)
- âœ… **Multi-sponsor model**: Registry funded by multiple pharma companies (2-3 AATD drug manufacturers contribute proportionally)â€”prevents single-company control, ensures balanced analysis

---

## Healthcare Corporation Partnerships

### Genetic Testing Partnerships

**Model**: Foundation promotes AATD genetic testing (diagnosis rates abysmalâ€”95% undiagnosed), lab offers discounted testing to Foundation referrals.

**Example**:
- **Lab**: University of Florida Alpha-1 Foundation Testing Lab (free AATD genetic testingâ€”funded by private donors)
- **Foundation's Role**: Promote testing via social media, support groups, physician outreach ("Suspect AATD? Get free test: [link]")
- **Lab's Benefit**: Patient volume (process 5,000 tests/year instead of 2,000â€”scale justifies continued funding)

**Contract Terms**:
> **Genetic Testing Collaboration Agreement**
>
> **Lab Responsibilities**:
> - Provide AATD genetic testing (genotype: PI*ZZ, PI*SZ, PI*MZ, etc.) at no cost to patients referred by Foundation
> - Mail test kits to patients (cheek swab, return prepaid envelope)
> - Return results within 4 weeks
> - Provide Foundation with aggregate data (# tests processed, genotype distributionâ€”for advocacy reports)
>
> **Foundation Responsibilities**:
> - Promote testing program (website, social media, support group announcements)
> - Refer 500-1,000 patients/year
> - Educate patients about importance of genetic testing
>
> **Data Sharing**: Lab provides Foundation quarterly reports (aggregate dataâ€”# tests, genotypes, statesâ€”no patient identifiable info without HIPAA authorization).
>
> **Patient Privacy**: Lab will not share patient contact info with Foundation (unless patient opts in to Foundation registry during test sign-up).

---

### Diagnostic Device Donations

**Model**: Medical device company donates equipment (spirometers, pulse oximeters) to Foundation for patient education events.

**Example**: Spirometer company donates 10 handheld spirometers ($500 each, $5K total)â€”Foundation uses at patient summits (patients learn how to measure lung function, practice with devices).

**In-Kind Donation Agreement**:
> **IN-KIND DONATION AGREEMENT**
>
> **Donor**: [Device Company]
> **Recipient**: Mark Egly Foundation
>
> **Donated Items**:
> - 10 handheld spirometers (Model XYZ, retail value $500 each)
> - Total value: $5,000
>
> **Use**: Foundation will use devices for patient education at:
> - Annual AATD Patient Summit (demonstrations, hands-on practice)
> - Regional support group meetings (loan devices to groups)
>
> **Acknowledgment**: Foundation will acknowledge Donor at events ("Spirometers provided by [Company]"), logo on event signage.
>
> **No Endorsement**: Acknowledgment â‰  endorsement (Foundation does not state device is "best" or "preferred"â€”one option among many).
>
> **Tax Receipt**: Foundation provides 501(c)(3) tax receipt (Donor can deduct $5K as charitable contribution).

---

## Sponsorship Agreements

### Event Sponsorship Tiers

**Model**: Foundation hosts annual AATD Patient Summit (200 attendees, $50K budget)â€”companies sponsor at tiered levels (Bronze $5K, Silver $10K, Gold $25K, Platinum $50K).

**Sponsor Benefits by Tier**:

| **Tier**        | **$ Amount** | **Benefits**                                                                                                   |
| --------------- | ------------ | -------------------------------------------------------------------------------------------------------------- |
| **Platinum**    | $50K         | Logo on all materials, 10-min speaking slot, exhibit booth, 4 summit tickets, logo on website (large), social media thank-you post, acknowledged in opening remarks |
| **Gold**        | $25K         | Logo on event materials, exhibit booth, 2 summit tickets, logo on website (medium), social media mention       |
| **Silver**      | $10K         | Logo on event program, 1 summit ticket, logo on website (small)                                                |
| **Bronze**      | $5K          | Logo on event program, name listed on website                                                                   |

---

### Sponsorship Agreement Template

**EVENT SPONSORSHIP AGREEMENT**

**Between**: [Sponsor Company] and Mark Egly Foundation

---

**1. SPONSORSHIP DETAILS**

**Event**: Mark Egly Foundation Annual AATD Patient Summit
**Date**: October 15, 2026
**Location**: Chicago, IL
**Expected Attendance**: 200 patients, caregivers, healthcare providers

**Sponsorship Level**: Gold ($25,000)

---

**2. SPONSOR BENEFITS**

**Recognition**:
- Logo on event signage (registration, main stage, meal bannersâ€”sized proportional to sponsorship tier)
- Logo in printed event program (full-page ad)
- Logo on Foundation website "Event Sponsors" page (6 months pre-event, 12 months post-event)
- Social media recognition (1 Facebook/Twitter post: "Thank you [Company] for supporting AATD patients!")

**Engagement**:
- Exhibit booth (10x10 space, table, 2 chairsâ€”company can display materials, talk to attendees)
- 2 complimentary summit tickets (company representatives attend, network)

**Content Opportunities** (Platinum Only, Not Included in Gold):
- Speaking slot not included (Foundation curates agendaâ€”prioritizes patient voices, medical experts, researchers over corporate speakers)
- If Sponsor wants to present, submit proposal (reviewed by Program Committeeâ€”approved based on educational value, not sponsorship level)

---

**3. SPONSOR RESPONSIBILITIES**

**Payment**:
- $25,000 due by August 1, 2026 (60 days pre-eventâ€”Foundation needs funds to finalize venue, catering contracts)
- Payment methods: Check, wire transfer, ACH

**Materials**:
- Provide high-res logo (vector formatâ€”EPS, AI, or PDF) by July 1, 2026
- Exhibit booth materials (banners, brochures) shipped to venue by October 10, 2026 (Sponsor's expense)

**Conduct**:
- Sponsor representatives will comply with Foundation's event policies (no aggressive sales tactics, respect patient privacy, focus on education not promotion)
- Promotional materials reviewed by Foundation in advance (Foundation reserves right to request removal of inappropriate contentâ€”e.g., drug price comparisons, competitor disparagement)

---

**4. FOUNDATION'S RESPONSIBILITIES**

**Event Execution**:
- Host well-organized summit (quality speakers, patient-relevant content, professional venue)
- Provide Sponsor with benefits listed in Section 2
- Introduce Sponsor during opening remarks ("Thank you to our Gold Sponsor, [Company]")

**Attendance**:
- Foundation targets 200 attendees (but does not guarantee specific #â€”attendance depends on patient interest, weather, competing events)
- If event canceled (force majeureâ€”COVID, natural disaster), Foundation offers: (1) Sponsor benefits at next year's summit, or (2) pro-rata refund (e.g., if 50% of budget spent before cancellation, refund 50%)

---

**5. LIMITATIONS**

**No Endorsement**:
- Sponsorship â‰  endorsement (Foundation does not endorse Sponsor's products/services)
- Foundation may not state "Official Sponsor" or "Preferred Partner" (implies exclusivity, endorsement)

**No Exclusivity**:
- Sponsor's competitors may also sponsor (if Pfizer sponsors, Grifols can tooâ€”Foundation accepts multiple pharma sponsors)
- Foundation will treat all sponsors equitably (same-tier sponsors get same-sized logos, same benefits)

**Editorial Independence**:
- Foundation retains control over event agenda, speakers, content (Sponsor may not dictate topics, demand competitor exclusion, require product promotion)

---

**6. TERMINATION**

**By Sponsor**: If Foundation materially breaches (e.g., fails to provide promised benefits), Sponsor may terminate, request refund (pro-rata if event already occurred).

**By Foundation**: If Sponsor engages in misconduct (violates event policies, misrepresents relationship as endorsement), Foundation may revoke sponsorship, no refund.

---

**7. SIGNATURES**

[ED and Sponsor authorized signatory]

---

## Brand Guidelines & Co-Branding

### Foundation Logo Usage by Partners

**Scenario**: Pharma company sponsors Foundation event, wants to use Foundation logo in their marketing ("We're proud to support Mark Egly Foundation").

**Foundation's Policy**: Allowed with restrictions (prevent misuse, protect brand).

---

### Logo Usage Guidelines

**âœ… ALLOWED**:
- "We support Mark Egly Foundation" (with Foundation logo next to statementâ€”accurate, factual)
- CSR reports ("2026 charitable partners: Mark Egly Foundation, [others]"â€”logo in list)
- Event marketing ("Join us at Mark Egly Foundation Summit"â€”if company has booth, accurate to use logo)

**âŒ PROHIBITED**:
- "Official partner of Mark Egly Foundation" (implies exclusivity, endorsementâ€”misleading)
- "Recommended by Mark Egly Foundation" (endorsementâ€”Foundation doesn't endorse products/services unless explicitly stated)
- "Mark Egly Foundation-certified [product]" (certification program doesn't existâ€”false claim)
- Altered logos (changing colors, stretching, adding textâ€”brand integrity)

---

### Logo Usage Agreement (Addendum to Partnership Contract)

> **LOGO USAGE TERMS**
>
> **Grant of License**: Foundation grants Partner limited, non-exclusive, non-transferable license to use Foundation name and logo solely for purposes of:
> - Acknowledging partnership (CSR reports, press releases, website)
> - Promoting joint events (if applicable)
>
> **Restrictions**:
> - Partner may not imply endorsement, exclusivity, or certification unless Foundation provides written authorization
> - Partner must submit proposed uses to Foundation for pre-approval (email draft to [Communications Manager]â€”5 business days for review)
> - Partner must use logo per Brand Guidelines (Appendix Aâ€”correct colors, spacing, size)
>
> **Consequences of Misuse**:
> - First violation: Foundation requests correction (Partner has 10 days to comply)
> - Second violation: Foundation revokes logo usage rights (Partner must cease all use)
> - Continued misuse: Foundation may terminate partnership, pursue legal remedies (trademark infringement, false advertising)

---

## Conflicts of Interest Management

### Foundation's Conflict of Interest Policy

**Scenario**: Board member works for pharma companyâ€”company proposes $200K grant to Foundation.

**Conflict**: Board member has dual loyalty (Foundation vs. employer)â€”may push Board to accept grant that benefits employer (even if not best deal for Foundation), or insider info leaks to employer.

---

### Conflict Management Protocol

**Step 1: Disclosure**:
- Board member discloses conflict at Board meeting ("I work for Company X, they're proposing grantâ€”I have conflict")
- Disclosure documented in meeting minutes

**Step 2: Recusal**:
- Board member leaves room during discussion + vote (may not participate, influence decision)
- Other Board members debate grant merits without conflicted member present

**Step 3: Decision**:
- Remaining Board votes (majority required to approve)
- If approved, minutes note conflict was disclosed, member recused

**Step 4: Ongoing Management**:
- Conflicted Board member may not be involved in grant administration (e.g., reviewing reports, communicating with company about grant)
- ED manages relationship with company (not Board member)

---

### Staff Conflicts

**Scenario**: ED's spouse works for pharma companyâ€”company proposes partnership.

**Management**:
- ED discloses to Board Chair (before negotiations)
- Board Chair appoints separate staff member (Development Director) to negotiate (ED recused)
- Board approves final contract (ED may provide input, but Board makes decision)

**Alternative** (If Conflict Severe):
- Decline partnership (e.g., ED's spouse is company's CEOâ€”too much appearance of impropriety, even if handled ethically)

---

## Foundation Independence Protections

### Why Independence Matters

**Risk**: Heavy reliance on corporate funding â†’ perception Foundation is "bought" â†’ patients distrust recommendations ("Of course Foundation says Drug X is greatâ€”they're funded by Company X").

**Mitigation**: Diversify funding, maintain editorial control, disclose transparently.

---

### Independence Safeguards

**1. Funding Diversification**:
- **Target**: No single corporate funder >20% of total revenue (if Company X provides $200K, total budget should be $1M+â€”ensures Foundation not dependent on one company)
- **Multiple pharma sponsors**: Partner with 2-3 AATD drug manufacturers (if only one, perception of favoritismâ€”multiple = balanced)

**2. Editorial Control**:
- **Unrestricted grants only**: Foundation does not accept "restricted" grants where company dictates content (e.g., "Grant funds webinar, but webinar must cover our drug"â€”no)
- **Content approval**: Foundation never allows corporate funders to pre-approve educational materials (undermines credibility)

**3. Transparent Disclosure**:
- **Website**: "Corporate Partners" page lists all funders ($10K+), updated quarterly
- **Annual report**: Revenue pie chart (individual donors 40%, corporate 25%, foundations 20%, government 10%, events 5%â€”transparency)
- **Sponsored content labeled**: "This program supported by educational grant from [Company]"â€”audience knows funding source

**4. Patient Advisory Committee**:
- **Consult patients before major corporate partnerships** ("We're considering $300K grant from Company Yâ€”thoughts?")â€”if patients object, reconsider
- **Annual survey**: "Do you trust Foundation's independence?" (if <80% say yes, investigateâ€”is corporate funding eroding trust?)

**5. Decline Certain Partnerships**:
- **Absolute no**: Tobacco companies, companies with egregious ethical violations (fraud convictions, patient harm scandals)
- **Case-by-case**: Companies with controversial reputations (opioid manufacturersâ€”AATD Foundation might decline due to opioid crisis, even if company donates to other health causes)

---

## Termination & Exit Clauses

### When to End Corporate Partnership

**Mutual Agreement** (Partnership Runs Course):
- Grant period ends (1-year grant, not renewedâ€”company's priorities shift, Foundation's needs change)
- Both parties satisfied, but no longer strategic fit

**Foundation-Initiated Termination**:
- **Company misconduct**: Scandal (fraud, patient harm), DOJ investigation, bankruptcyâ€”Foundation doesn't want association
- **Breach of contract**: Company misrepresents relationship as endorsement (after warnings), attempts to control content
- **Mission drift**: Company pivots away from AATD (sells AATD drug division), partnership no longer relevant

**Company-Initiated Termination**:
- **Budget cuts**: Company restructures, eliminates philanthropic program
- **Strategic shift**: Company focuses CSR on different disease areas (exits rare disease space)

---

### Termination Clause Template

> **TERMINATION**
>
> **Term**: This Agreement effective January 1, 2026 - December 31, 2026.
>
> **Renewal**: Parties may renew annually by mutual written agreement (90 days before expiration).
>
> **Termination for Cause**:
> - Either party may terminate immediately if other party materially breaches (written notice, describe breach)
> - Breaching party has 30 days to cure (if curable)
> - If not cured, termination effective
>
> **Termination for Convenience**:
> - Either party may terminate without cause (90 days written notice)
>
> **Effect of Termination**:
> - **Grants**: If Foundation terminates Company's grant, Foundation returns unused funds (pro-rata) within 60 days
> - **Sponsorships**: If Foundation terminates before event, Foundation refunds sponsorship fee (minus costs already incurredâ€”e.g., if logo already printed on 500 programs, Foundation deducts printing cost)
> - **Logo usage**: Upon termination, Company must cease using Foundation logo within 30 days (remove from website, marketing materials)
> - **Acknowledgments**: Company may reference past partnership factually ("In 2026, we supported Mark Egly Foundation"â€”accurate historical statement, not ongoing endorsement)

---

## Legal & Tax Considerations

### IRS Rules for Corporate Sponsorships

**Tax Law**: Corporations can deduct charitable contributions (sponsorships, grants) IF:
- âœ… **Qualified 501(c)(3)**: Foundation is IRS-recognized charity (deduction-eligible)
- âœ… **Acknowledgment, not advertising**: Foundation acknowledges sponsor (logos, thank-yousâ€”okay), but if Foundation advertises sponsor's products ("Buy Drug X!"â€”not okay, becomes taxable "unrelated business income" for Foundation)

---

### Qualified Sponsorship Payment (QSP) vs. Advertising

**IRS Definition**:

**Qualified Sponsorship Payment** (Tax-Free to Foundation):
- âœ… "This event supported by Company X" (neutral acknowledgment)
- âœ… Company logo, name, location, phone, website (identifying infoâ€”okay)
- âœ… "Company X manufactures AATD treatments" (factual description of businessâ€”okay)

**Advertising** (Taxable to Foundation):
- âŒ "Buy Drug X from Company Xâ€”best AATD treatment!" (endorsement, call-to-actionâ€”advertising, Foundation owes Unrelated Business Income Tax on sponsorship $)
- âŒ Comparative claims ("Company X's drug is superior to competitors"â€”advertising)

**Foundation's Policy**: Keep sponsorships as QSPs (neutral acknowledgments, no advertisingâ€”avoids tax complications).

---

### Tax Receipts

**For Cash Grants/Sponsorships**:
- Foundation provides 501(c)(3) tax receipt (Company can deduct full amountâ€”no goods/services provided in exchange)
- Receipt includes: Foundation EIN, donation amount, date, statement "No goods or services provided in exchange for this contribution" (IRS requirement for full deductibility)

**For In-Kind Donations** (Equipment, Services):
- Foundation provides receipt acknowledging donation (description of items, but NOT valuationâ€”IRS rules: donor determines fair market value, not recipient)
- Receipt: "Acknowledged receipt of 10 spirometers (Model XYZ). No goods or services provided in exchange. Mark Egly Foundation is a 501(c)(3) organization, EIN: XX-XXXXXXX."

---

## Budget & Resources

### Year 1-3 Corporate Partnership Budget ($50K-$150K Annual Revenue)

**Partnerships**:
- 1-2 small sponsorships ($5K-$10K eachâ€”local businesses, event sponsors)
- 1 pilot pharma grant ($25K-$50Kâ€”unrestricted educational grant)

**Personnel**:
- Development Director (20% time on corporate partnerships, ~$15K allocation)

**Expenses**:
- Sponsorship materials (logos, signage, program printingâ€”$2K-$5K)
- Legal review (1-2 contracts/year, $1K-$3K)

**Net Revenue**: $30K-$100K (after expenses)

---

### Year 4-7 Corporate Partnership Budget ($200K-$500K Annual Revenue)

**Partnerships**:
- 3-5 event sponsors ($5K-$25K each, total $50K-$100K)
- 2-3 pharma grants ($50K-$150K each, total $150K-$300K)
- 1-2 healthcare corporate partnerships ($25K-$50Kâ€”genetic testing, device donations)

**Personnel**:
- Development Director (50% time, ~$35K)
- Corporate Relations Coordinator (0.5 FTE, $30Kâ€”manage sponsor fulfillment, logo usage, reporting)

**Expenses**:
- Sponsorship fulfillment ($10K-$20Kâ€”event signage, recognition materials)
- Legal review ($5K-$10Kâ€”3-5 contracts/year)
- Due diligence (subscription to nonprofit databases, background checksâ€”$1K-$3K)

**Net Revenue**: $150K-$400K

---

### Year 8-10 Corporate Partnership Budget ($500K-$1M Annual Revenue)

**Partnerships**:
- 5-10 event sponsors ($5K-$50K, total $100K-$200K)
- 4-6 pharma grants ($100K-$250K each, total $400K-$700K)
- 2-4 healthcare corporate partnerships ($50K-$100K, total $100K-$200K)

**Personnel**:
- Corporate Relations Manager (1.0 FTE, $70Kâ€”oversee all corporate partnerships)
- Corporate Relations Coordinator (1.0 FTE, $60Kâ€”fulfillment, reporting, stewardship)
- Development Director (20% time, ~$15Kâ€”strategic oversight)

**Expenses**:
- Sponsorship fulfillment ($20K-$40Kâ€”professional signage, videos, higher production value)
- Legal review ($10K-$20Kâ€”6-10 contracts/year, complex negotiations)
- Corporate events (VIP donor receptions, site visitsâ€”$10K-$20K)

**Net Revenue**: $400K-$800K

---

**Document Owner**: Executive Director & Development Director
**Review Frequency**: Annually (adjust policies based on IRS guidance, partnership experiences)
**Board Oversight**: Board reviews all corporate partnerships >$50K (approve before signing), Development Committee monitors portfolio quarterly
**Cross-References**:
- Conflict of Interest Policy (Document 14â€”Board/staff conflict management)
- Fundraising Strategy (existingâ€”corporate giving as revenue stream)
- Grant Management Lifecycle (Document 23â€”grant administration, reporting)
- Academic Partnership Agreements (Document 29â€”research funding comparisons)

---

**Last Updated**: November 9, 2025
**Next Review**: November 2026
